Evidence review
GLP-1 shortages & supply: what's going on and what it means for you
How the FDA drug-shortage list shaped the GLP-1 market, why brand supply recovered, and what the shift means for compounded access and your refills.
Supply is the quiet force behind almost everything in the GLP-1 market — which products you can get, at what price, and from whom. For a couple of years the story was scarcity; more recently it's been recovery, with a twist. Here's where things stand and what it means for the medication in your fridge, current as of mid-2026.
The shortage years
As demand for semaglutide and tirzepatide exploded, the manufacturers couldn't keep up, and both molecules spent extended stretches on the FDA drug-shortage list1. If you tried to fill a brand-name prescription during that window, you may have hit pharmacies that simply didn't have your dose. The shortage list is a public database the FDA maintains, and it's the single best place to check the official status of a drug's supply1.
Why a shortage fueled the compounding boom
Here's the connection that surprises people: the shortage is what made large-scale compounding possible. When a drug is officially in shortage, compounding pharmacies have more latitude to prepare copies of it — that's a deliberate safety valve so patients aren't left without medication2. That latitude is a big reason the cash-pay, compounded GLP-1 market grew as fast as it did. The regulatory background is covered in is compounded semaglutide legit?.
The recovery — and the wind-down
As the manufacturers scaled up, the brand-name products came off the shortage list. That's good news for anyone who wants Wegovy or Zepbound, but it changed the ground under the compounded market: once a drug is no longer in shortage, the latitude that let compounders make copies at scale narrows. In practical terms, the compounded market moved from 'wide open' to 'legal but under closer FDA attention,' which is exactly the phase it's in now. Providers that named their sourcing and built stable pharmacy relationships are better positioned for this than ones that didn't.
What it means for you
A few takeaways. First, if you're on a compounded program, don't assume today's price and availability are permanent — the regulatory picture is still settling, and that can affect both. Second, if continuity matters to you, favor a provider with a demonstrated, disclosed supply chain over one that's cagey about where your medication comes from; supply reliability is one of the six factors in our Brief Score for exactly this reason. Third, if you ever want to verify a brand drug's official status yourself, go straight to the FDA's shortage database rather than relying on a marketing page1.
How this connects to price
Supply and price are two sides of the same coin. When supply is tight, prices firm up and teaser deals disappear; when it loosens, competition pushes prices down — until a regulatory shift tightens things again. If you want to understand why your monthly cost moves the way it does, read why GLP-1 prices move, and use our provider briefs to see which desks have held steady through the churn. This is market context, not medical advice — for anything about your own treatment, talk to your clinician.
Frequently asked questions
Are GLP-1 drugs still in shortage?
The brand-name products moved off the FDA shortage list as manufacturing scaled up, though status can change. The FDA drug-shortage database is the authoritative place to check any drug's current official supply status.
How did the shortage affect compounded GLP-1s?
When a drug is officially in shortage, compounding pharmacies have more latitude to make copies of it. That safety valve fueled the compounded GLP-1 boom. As the brand shortages resolved, that latitude narrowed, which is why the compounded market is under closer FDA attention now.
How can I protect my own supply?
Favor a provider that discloses its pharmacy sourcing and has a stable track record, don't assume current pricing and availability are permanent, and verify any brand drug's official status directly in the FDA shortage database.
References
- U.S. Food and Drug Administration (2025). FDA Drug Shortages database. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
How to choose a GLP-1 provider: a 5-minute checklist
A plain-English, five-minute checklist for vetting a GLP-1 telehealth provider — price stability, accreditation, supply, and the fine print that matters.
ReadCompounded vs brand-name GLP-1, explained
What separates compounded semaglutide and tirzepatide from brand-name Wegovy and Zepbound — on price, regulation, supply, and what the labels actually cover.
ReadSemaglutide vs tirzepatide: what the trials actually show
A plain-English read of the STEP-1, SURMOUNT-1, and SURPASS-2 trials: how much weight each GLP-1 drove, in which patients, and what the head-to-head compared.
ReadWhy GLP-1 prices move: teaser rates, step-ups, and supply
The forces behind GLP-1 pricing — teaser rates, month-two step-ups, stacked fees, and supply — and how to read a monthly price so it won't surprise you.
ReadIs compounded semaglutide legit? What to check
A measured look at compounded semaglutide: what 503A and 503B pharmacies are, what LegitScript and FDA rules cover, and the checks that flag a safe desk.
Read